Circulating Levels of Pealbumin in Relation to Overweight or Obesity
Independent Relationship Between Prealbumin and Circulating Levels of Parathormone Triglycerides and FT3 in Subjects With Overweight or Obesity
1 other identifier
observational
84
1 country
1
Brief Summary
The study was aimed to investigating the relationship between circulating level of prealbumin and parathormone (PTH), triglycerides and triiodothyronine (FT3) in overweight and obese subjects (BMI≥25 Kg/m2)
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jan 2019
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 7, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 26, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2019
CompletedFirst Submitted
Initial submission to the registry
April 1, 2020
CompletedFirst Posted
Study publicly available on registry
April 3, 2020
CompletedMay 18, 2020
May 1, 2020
7 months
April 1, 2020
May 15, 2020
Conditions
Outcome Measures
Primary Outcomes (4)
Prealbumin
Prealbumin (g/L) concentration in serum
baseline
Free Triiodothyronine (FT3)
FT3 (pg/mL) concentration in serum
baseline
Parathormone (PTH)
PTH (pg/mL) concentration in serum
baseline
Triglycerides
Triglycerides (mg/dl) concentration in serum
baseline
Secondary Outcomes (3)
Height
baseline
Weight
baseline
Body mass Index (BMI)
baseline
Eligibility Criteria
Patients who came to the Outpatient Clinic of Nutrition at the National Institute of Gastroenterology "S. de Bellis," Research Hospital, Castellana Grotte, Italy.
You may qualify if:
- Overweight or obesity (BMI\> 25 Kg/m2)
You may not qualify if:
- Any kind of drug Hypertension Endocrine diseases (diabetes mellitus, hypo or hyperthyroidism, hypopituitarism, etc.), Chronic inflammatory diseases Renal failure Liver failure Angina pectoris Myocardial infarction and heart failure Genetic heart diseases Thrombocytopenias
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Luisa Lampignano
Castellana Grotte, 70013, Italy
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Clinical Professor
Study Record Dates
First Submitted
April 1, 2020
First Posted
April 3, 2020
Study Start
January 7, 2019
Primary Completion
July 26, 2019
Study Completion
December 31, 2019
Last Updated
May 18, 2020
Record last verified: 2020-05
Data Sharing
- IPD Sharing
- Will not share